Q3'25 Earnings Presentation October 30, 2025 Forward-Looking Statements Statements in this release that are not historical are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, include, but are not limited to, statements regarding: our business strategy; anticipated future operating results and operating expenses, cash flows, capita ...

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to extend its duration by one year to October 30, 2026, in response to significant dislocation in the trading price of its common stock [1][2] Summary by Sections Rights Plan Amendment - The amendment aims to increase potential dilution for any Acquiring Person if the Rights Plan is triggered, allowing stockholders to realize long-term value and reducing the likelihood of control by any person or group without proper compensation [2][4] - The Rights Plan will automatically expire on October 30, 2026, unless redeemed or exchanged earlier by the Company [4] Acquisition and Control - The Board did not adopt the extension in response to a specific takeover threat and retains the ability to engage with parties or accept acquisition proposals if deemed in the best interests of the Company and its stockholders [3] Rights Plan Details - The Rights become exercisable if an Acquiring Person acquires 10% or more of the outstanding common stock (15% for passive institutional investors) [4] - Stockholders above the threshold at the initial announcement are grandfathered but cannot increase ownership without triggering the Rights Plan [4] - Each Right allows the holder to purchase additional shares at $20.00, with a market value of twice the exercise price [4] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines, with a pipeline addressing underserved therapeutic areas [6]

Q2'25 Performance Highlights - Increased total sales volumes by 6% compared with Q2'24, driven by UAN and AN sales[10] - Net sales increased to $151 million in Q2'25 from $140 million in Q2'24[17] - Adjusted EBITDA was $38 million in Q2'25, compared to $42 million in Q2'24[17] - Adjusted EBITDA margin decreased to 25% in Q2'25 from 30% in Q2'24[17] - Diluted EPS was $004 in Q2'25, compared to $013 in Q2'24[17] Balance Sheet and Capital Allocation - Reduced debt by $32 million[10] - Cash and short-term investments were $125 million as of June 30, 2025, compared to $216 million as of June 30, 2024[23] - Total debt was $453 million as of June 30, 2025, compared to $486 million as of June 30, 2024[23] - Net debt to TTM Adjusted EBITDA was 27x[23] El Dorado CCS Project - The El Dorado low carbon ammonia project is progressing towards a 2H'26 startup[10]